Racial differences in urinary F2-isoprostane levels and the cross-sectional association with bmi

Obesity

Volumn 20, Issue 10, 2012, Pages 2147-2150

  Il'Yasova, Dora ^a   Wang, Frances ^a   Spasojevic, Ivan ^a   Base, Karel ^a   D'Agostino Jr , Ralph B ^b   Wagenknecht, Lynne E ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DINOR F2A ISOPROSTANE III; 8,12 F2A ISOPROSTANE VI; F2A ISOPROSTANE III; F2A ISOPROSTANE VI; ISOPROSTANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; INSULIN RESISTANCE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; OBESITY; PROSTAGLANDIN URINE LEVEL; RACE DIFFERENCE; RISK ASSESSMENT; TANDEM MASS SPECTROMETRY; URINALYSIS;

ADULT; AFRICAN AMERICANS; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; F2-ISOPROSTANES; FEMALE; HISPANIC AMERICANS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; PROSPECTIVE STUDIES; TANDEM MASS SPECTROMETRY; UNITED STATES; WEIGHT GAIN;

EID: 84866739096     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2012.170     Document Type: Article

References (24)

1. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 2008;10:1405-1434.
2. Keaney JF Jr, Larson MG, Vasan RS et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23:434-439.
3. Meigs JB, Larson MG, Fox CS et al. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 2007;30:2529-2535.
4. Il'yasova D, Spasojevic I, Base K et al. Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes. Diabetes Care 2012 35: 173-174.
5. Il'yasova D, Wang F, Spasojevic I, et al. Urinary F2-Isoprostanes, obesity, and weight gain in the IRAS cohort. Obesity 2011, (doi:10.1038/oby. 2011.292).
6. Kanaya AM, Wassel CL, Stoddard PJ et al. F2-isoprostanes and adiposity in older adults. Obesity (Silver Spring) 2011;19:861-867.
7. Il'yasova D, Morrow JD, Wagenknecht LE. Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obes Res 2005;13:1638-1644.
8. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
9. Kaiyala KJ, Schwartz MW. Toward a more complete (and less controversial) understanding of energy expenditure and its role in obesity pathogenesis. Diabetes 2011;60:17-23.
10. Weyer C, Pratley RE, Salbe AD et al. Energy expenditure, fat oxidation, and body weight regulation: a study of metabolic adaptation to long-term weight change. J Clin Endocrinol Metab 2000;85:1087-1094.
11. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, Georgia, 2011.
12. Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol 2003;40 (Suppl 1): S302-S304.
13. Goran MI. Ethnic-specific pathways to obesity-related disease: the Hispanic vs. African-American paradox. Obesity (Silver Spring) 2008;16:2561-2565.
14. Lutsey PL, Pereira MA, Bertoni AG, Kandula NR, Jacobs DR Jr. Interactions between race/ethnicity and anthropometry in risk of incident diabetes: the multi-ethnic study of atherosclerosis. Am J Epidemiol 2010;172:197-204.
15. Yan W, Byrd GD, Ogden MW. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J Lipid Res 2007;48:1607-1617.
16. WHO. Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985;727:1-113.
17. Praticò D, Barry O P, Lawson JA et al. IPF2alpha-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci USA 1998;95:3449-3454.
18. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000;28:505-513.
19. Zhang H, Il'yasova D, Sztaray J et al. Quantification of the oxidative damage biomarker 2, 3-dinor-8-isoprostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry. Anal Biochem 2010;399:302-304.
20. Il'yasova D, Spasojevic I, Wang F et al. Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev 2010 19: 1506-1510.
21. Barr DB, Wilder LC, Caudill SP et al. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect 2005;113:192-200.
22. Dorjgochoo T, Gao YT, Chow WH et al. Obesity, age, and oxidative stress in middle-aged and older women. Antioxid Redox Signal 2011;14:2453-2460.
23. Urakawa H, Katsuki A, Sumida Y et al. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab 2003;88:4673-4676.
24. Weyer C, Snitker S, Bogardus C, Ravussin E. Energy metabolism in African Americans: potential risk factors for obesity. Am J Clin Nutr 1999;70:13-20.